134 related articles for article (PubMed ID: 35278028)
21. A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.
Takada M; Parys M; Gregory-Bryson E; Vilar Saavedra P; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2018 Mar; 18(1):237. PubMed ID: 29490634
[TBL] [Abstract][Full Text] [Related]
22. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
[TBL] [Abstract][Full Text] [Related]
23. Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed.
Abadie J; Hédan B; Cadieu E; De Brito C; Devauchelle P; Bourgain C; Parker HG; Vaysse A; Margaritte-Jeannin P; Galibert F; Ostrander EA; André C
J Hered; 2009; 100 Suppl 1(Suppl 1):S19-27. PubMed ID: 19531730
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis inhibitor of macrophage (AIM) reduces cell number in canine histiocytic sarcoma cell lines.
Uchida M; Saeki K; Maeda S; Tamahara S; Yonezawa T; Matsuki N
J Vet Med Sci; 2016 Oct; 78(9):1515-1520. PubMed ID: 27246397
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
Zavodovskaya R; Liao AT; Jones CL; Yip B; Chien MB; Moore PF; London CA
Am J Vet Res; 2006 Apr; 67(4):633-41. PubMed ID: 16579756
[TBL] [Abstract][Full Text] [Related]
26. Clinical prognostic factors in canine histiocytic sarcoma.
Dervisis NG; Kiupel M; Qin Q; Cesario L
Vet Comp Oncol; 2017 Dec; 15(4):1171-1180. PubMed ID: 27334037
[TBL] [Abstract][Full Text] [Related]
27. A 2-base insertion in exon 5 is a common mutation of the TP53 gene in dogs with histiocytic sarcoma.
Asada H; Tsuboi M; Chambers JK; Uchida K; Tomiyasu H; Goto-Koshino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2017 Oct; 79(10):1721-1726. PubMed ID: 28867679
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinases expression in spontaneous canine histiocytic sarcomas and its xenograft model.
Fayyad A; Lapp S; Risha E; Pfankuche VM; Rohn K; Barthel Y; Schaudien D; Baumgärtner W; Puff C
Vet Immunol Immunopathol; 2018 Apr; 198():54-64. PubMed ID: 29571518
[TBL] [Abstract][Full Text] [Related]
29. Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior.
Hedan B; Thomas R; Motsinger-Reif A; Abadie J; Andre C; Cullen J; Breen M
BMC Cancer; 2011 May; 11():201. PubMed ID: 21615919
[TBL] [Abstract][Full Text] [Related]
30. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
Massoth LR; Hung YP; Ferry JA; Hasserjian RP; Nardi V; Nielsen GP; Sadigh S; Venkataraman V; Selig M; Friedmann AM; Samore W; Killian JK; Milante R; Giessinger J; Foley-Peres K; Marcus C; Severson E; Duncan D; Sivakumar S; Ross JS; Desphande V; Ramkissoon SH; Vergilio JA; Louissaint A; Zukerberg LR; Williams EA
Oncologist; 2021 Jul; 26(7):e1263-e1272. PubMed ID: 33904632
[TBL] [Abstract][Full Text] [Related]
31. RNA in situ hybridisation as a molecular diagnostic technique targeting IBA-1 and CD204 in canine histiocytic sarcoma.
Engelien JL; Lejeune AT; Dark MJ; Milner RJ; Shiomitsu K
Vet Med Sci; 2022 Jul; 8(4):1400-1408. PubMed ID: 35339118
[TBL] [Abstract][Full Text] [Related]
32. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
[TBL] [Abstract][Full Text] [Related]
33. Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.
Takada M; Smyth LA; Hix JM; Corner SM; Kiupel M; Yuzbasiyan-Gurkan V
Comp Med; 2019 Feb; 69(1):22-28. PubMed ID: 30717820
[TBL] [Abstract][Full Text] [Related]
34. Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcoma.
Asada H; Tani A; Sakuma H; Hirabayashi M; Matsumoto Y; Watanabe K; Tsuboi M; Yoshida S; Harada K; Uchikai T; Goto-Koshino Y; Chambers JK; Ishihara G; Kobayashi T; Irie M; Uchida K; Ohno K; Bonkobara M; Tsujimoto H; Tomiyasu H
Sci Rep; 2023 May; 13(1):8512. PubMed ID: 37231193
[TBL] [Abstract][Full Text] [Related]
35. Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
Thaiwong T; Sirivisoot S; Takada M; Yuzbasiyan-Gurkan V; Kiupel M
Vet Comp Oncol; 2018 Jun; 16(2):220-228. PubMed ID: 28929581
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
Igase M; Shousu K; Fujiki N; Sakurai M; Bonkobara M; Hwang CC; Coffey M; Noguchi S; Nemoto Y; Mizuno T
Vet Comp Oncol; 2019 Jun; 17(2):184-193. PubMed ID: 30761736
[TBL] [Abstract][Full Text] [Related]
37. Histiocytic and dendritic neoplasms.
Skoog L; Tani E
Monogr Clin Cytol; 2009; 18():56-9. PubMed ID: 19092263
[No Abstract] [Full Text] [Related]
38. Clinical significance of the two-base insertion mutation in the TP53 gene in canine histiocytic sarcoma.
Asada H; Tomiyasu H; Okada K; Chambers JK; Goto-Koshino Y; Uchida K; Kagawa Y; Ohno K; Tsujimoto H
Res Vet Sci; 2019 Jun; 124():57-60. PubMed ID: 30852355
[TBL] [Abstract][Full Text] [Related]
39. Canine histiocytic neoplasia: an overview.
Fulmer AK; Mauldin GE
Can Vet J; 2007 Oct; 48(10):1041-3, 1046-50. PubMed ID: 17987966
[TBL] [Abstract][Full Text] [Related]
40. Utilization of cytoplasmic lysozyme immunoreactivity as a histiocytic marker in canine histiocytic disorders.
Moore PF
Vet Pathol; 1986 Nov; 23(6):757-62. PubMed ID: 3027941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
